SOSEI

  • CONTACT US
  • SITE MAP
  • JAPANESE
  • HOME
  • About us
  • Our business model
  • Investors
  • Newsroom
About us
TOPへ
  • A message from the President
  • About Sosei Group
  • The story behind our name
  • Corporate overview
    • Locations
  • Our mission and vision
  • Corporate governance
  • Management team
  • Our history
  • Our subsidiaries
Our business model
TOPへ
  • Business model
    • Heptares GPCR drug discovery
    • Activus nanoparticle technology
    • Jitsubo peptide technologies
  • Products and pipeline
    • Seebri®/NVA237
    • Ultibro®/QVA149
    • NorLevo® 0.75mg
    • SO-1105
  • Our partners
Investors
TOPへ
  • Our philosophy and strategy
    • Mid-term financial forecast
    • Business risks
    • Disclosure policy
  • Financial information
    • Financial highlights
    • Financial data
  • Reports and presentations
    • Financial reports
    • Presentation material and webcasts
  • Shareholder information
    • Share information
    • Annual General Meeting
    • Share price analysis
    • Share ownership
    • Analyst coverage
  • News alerts
  • Disclaimer
Newsroom
TOPへ
  • NEWS
  • Events
  • Multimedia centre
CLOSE
 
  • HOME
  • About us
  • Our mission and vision

Our mission and vision

  • VISION
  • MISSION
  • CORE VALUES
About us
  • A message from the President
  • About Sosei Group
  • The story behind our name
  • Corporate overview
    • Locations
  • Our mission and vision
  • Corporate governance
  • Management team
  • Our history
  • Our subsidiaries
Page top
  • Privacy policy
  • Terms of use
© Sosei Group. All rights reserved.